Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2

CPA Ivory, LE Wallace… - American Journal of …, 2008 - journals.physiology.org
CPA Ivory, LE Wallace, DM McCafferty, DL Sigalet
American Journal of Physiology-Gastrointestinal and Liver …, 2008journals.physiology.org
Glucagon-like peptide 2 (GLP-2) is an important intestinal growth factor with anti-
inflammatory activity. We hypothesized that GLP-2 decreases mucosal inflammation and the
associated increased epithelial proliferation by downregulation of Th1 cytokines attributable
to reprogramming of lamina propria immune regulatory cells via an interleukin-10 (IL-10)-
independent pathway. The effects of GLP-2 treatment were studied using the IL-10-deficient
(IL-10−/−) mouse model of colitis. Wild-type and IL-10−/− mice received saline or GLP-2 (50 …
Glucagon-like peptide 2 (GLP-2) is an important intestinal growth factor with anti-inflammatory activity. We hypothesized that GLP-2 decreases mucosal inflammation and the associated increased epithelial proliferation by downregulation of Th1 cytokines attributable to reprogramming of lamina propria immune regulatory cells via an interleukin-10 (IL-10)-independent pathway. The effects of GLP-2 treatment were studied using the IL-10-deficient (IL-10−/−) mouse model of colitis. Wild-type and IL-10−/− mice received saline or GLP-2 (50 μg/kg sc) treatment for 5 days. GLP-2 treatment resulted in significant amelioration of animal weight loss and reduced intestinal inflammation as assessed by histopathology and myeloperoxidase levels compared with saline-treated animals. In colitis animals, GLP-2 treatment also reduced crypt cell proliferation and crypt cell apoptosis. Proinflammatory (IL-1β, TNF-α, IFN-γ,) cytokine protein levels were significantly reduced after GLP-2 treatment, whereas IL-4 was significantly increased and IL-6 production was unchanged. Fluorescence-activated cell sorting analysis of lamina propria cells demonstrated a decrease in the CD4+ T cell population following GLP-2 treatment in colitic mice and an increase in CD11b+/F4/80+ macrophages but no change in CD25+FoxP3 T cells or CD11c+ dendritic cells. In colitis animals, intracellular cytokine analysis demonstrated that GLP-2 decreased lamina propria macrophage TNF-α production but increased IGF-1 production, whereas transforming growth factor-β was unchanged. GLP-2-mediated reduction of crypt cell proliferation was associated with an increase in intestinal epithelial cell suppressor of cytokine signaling (SOCS)-3 expression and reduced STAT-3 signaling. This study shows that the anti-inflammatory effects of GLP-2 are IL-10 independent and that GLP-2 alters the mucosal response of inflamed intestinal epithelial cells and macrophages. In addition, the suggested mechanism of the reduction in inflammation-induced proliferation is attributable to GLP-2 activation of the SOCS-3 pathway, which antagonizes the IL-6-mediated increase in STAT-3 signaling.
American Physiological Society